KTTA · Pasithea Therapeutics Corp.
$0.45
+0.00 (+0.00%)
At close · Jul 29
Market Cap
$15.04M
Shares
33.41M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dr. Tiago Reis Marques | CEO | $640,059 |
| Daniel Schneiderman | CFO | $430,223 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dr. Tiago Reis Marques | CEO | $537,347 |
| Graeme Currie | Chief Development Officer | $444,864 |
| Daniel Schneiderman | CFO | $345,939 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Tiago Reis Marques | CEO | $539,250 |
| Daniel Schneiderman | CFO | $367,203 |
| Graeme Currie | Chief Development Officer | $198,870 |
| Stanley M. Gloss | CFO | $60,000 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dr. Tiago Reis Marques | CEO | $671,891 |
| Stanley M. Gloss | CFO | $412,165 |
| Daniel Schneiderman | CFO | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Stanley M. Gloss | CFO | — |
| Dr. Tiago Reis Marques | CEO | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kartik Krishnan, M.D., Ph.D. | Chief Medical Officer | Appointed | 2026-05-04 |